Open AccessRanibizumab for the Treatment of Choroidal Neovascularisation due to Causes other than Age-Related Macular Degeneration
Author(s) -
Alexandr Stěpanov,
Markéta Středová,
J Dusová,
N Jirásková,
Jan Studnička
Publication year - 2019
Publication title -
czech and slovak ophthalmology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.178
H-Index - 11
eISSN - 1805-4447
pISSN - 1211-9059
DOI - 10.31348/2019/3/4
Subject(s) - macular degeneration , pro re nata , medicine , choroidal neovascularization , ranibizumab , ophthalmology , drusen , angioid streaks , visual acuity , diabetic retinopathy , serous fluid , surgery , bevacizumab , diabetes mellitus , chemotherapy , endocrinology
To evaluate the safety and clinical efficacy of ranibizumab (Lucentis) in the treatment of choroidal neovascularization (CNV) caused by diseases other than age-related macular degeneration (AMD).
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom